A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December...

Full description

Saved in:
Bibliographic Details
Main Authors: Weiping Liu, Donglu Zhao, Ting Liu, Ting Niu, Yongping Song, Wei Xu, Jie Jin, Qingqing Cai, Huiqiang Huang, Zhiming Li, Ming Hou, Huilai Zhang, Jianfeng Zhou, Jianda Hu, Jianzhen Shen, Yuankai Shi, Yu Yang, Liling Zhang, Weili Zhao, Kaiyang Ding, Lugui Qiu, Huo Tan, Zhihui Zhang, Lihong Liu, Jinghua Wang, Bing Xu, Hui Zhou, Guangxun Gao, Hongwei Xue, Ou Bai, Ru Feng, Xiaobing Huang, Haiyan Yang, Xiaojing Yan, Qingshu Zeng, Peng Liu, Wenyu Li, Min Mao, Hang Su, Xin Wang, Jingyan Xu, Daobin Zhou, Hongyu Zhang, Jun Ma, Zhixiang Shen, Jun Zhu
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
lymphoma
T-cell
peripheral
histone deacetylase inhibitors
efficiency
safety
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/5c9000aa953646639a5acb21ddd9d292
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/5c9000aa953646639a5acb21ddd9d292

Similar Items